SB000
Age-related Hearing Loss
Pre-clinicalActive
Key Facts
About Shift Bioscience
Shift Bioscience is an early-stage biotech pioneering an AI-powered approach to cellular rejuvenation, aiming to treat age-related diseases by reversing epigenetic aging signatures. Its core technology platform identifies gene targets that safely reverse aging clocks, with a lead program (SB000) targeting age-related hearing loss and a pipeline exploring liver fibrosis and systemic sclerosis. The company operates from Cambridge, UK, and Toronto, Canada, positioning itself at the intersection of computational biology and traditional therapeutic development to address the fundamental biology of aging.
View full company profileTherapeutic Areas
Other Age-related Hearing Loss Drugs
| Drug | Company | Phase |
|---|---|---|
| GTI-850 | GSNO Therapeutics | Pre-clinical |
| ACOU085 (Bimokalner) | Acousia Therapeutics | Phase 2 |
| Preclinical Kv3 Modulators | Autifony Therapeutics | Preclinical |